Neurophet Supplies 'Neurophet AQUA' and 'Neurophet AQUA AD Plus' to Elevate Clinic in the U.S., Expanding Its Presence in the U.S. Brain Disorders Market
Provides solutions for analyzing brain atrophy and white matter hyperintensities, as well as monitoring side effects associated with Alzheimer's disease treatments Secures a key reference site at a U.S. medical institution specializing in...
Neurophet Showcases 'Brain Imaging AI Solutions' at BIO USA, Accelerates Global Business Development Collaborations
Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease treatment decision-making Expands partnering efforts with global pharmaceutical and biotech companies as well as potential customers, while...
Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone
Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports...